Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year
Journal
LUTS: Lower Urinary Tract Symptoms
Journal Volume
10
Journal Issue
1
Pages
21-26
Date Issued
2018
Author(s)
Abstract
Objectives: Details on the therapeutic effects of long-term antimuscarinic therapy have not been reported. Thus, the aim of this study is to evaluate the detailed long-term therapeutic effect of antimuscarinic therapy. Methods: All consecutive patients who visited the urologic outpatient clinics of a medical center for treatment of overactive bladder syndrome and received antimuscarinic therapy of 12 months or more were retrospectively reviewed. All medical records, including the Overactive Bladder Symptom score (OABSS), the modified Indevus Urgency Severity Scale and the International Prostate Symptoms score (IPSS) questionnaires, and uroflowmetry parameters were reviewed at each visit. Results: A total of 140 patients had received 12 months or more of antimuscarinic therapy. Sustained therapeutic effects were observed by persistent decreases of IPSS-storage score, IPSS-total score and OABSS score. Moreover, the maximum flow rate did not change over time. A temporary increase in postvoid residual volume and decrease in voiding efficiency were found, but these parameters improved over long-term visits. Side-effects were observed in 81 patients (57.9%) and included dry mouth (n = 58, 41.4%), constipation (n = 48, 34.3%) and blurred vision (n = 4, 2.9%); all side-effects were tolerable. Patients aged 75 years or more (n = 94) had a higher comorbidity rate (n = 46, 48.9%) before treatment but generally exhibited similar therapeutic effects as overall patients; elderly patients could also tolerate side-effects. Conclusion: Sustained therapeutic effects were observed in patients who received 12 months or more of antimuscarinic therapy, even in elderly patients. In addition, side-effects in patients receiving long-term therapy were also common but tolerable. ? 2016 John Wiley & Sons Australia, Ltd
SDGs
Other Subjects
oxybutynin; solifenacin; tolterodine; mandelic acid derivative; muscarinic receptor blocking agent; oxybutynin; solifenacin; tolterodine; adult; aged; Article; blurred vision; comorbidity; constipation; drug effect; drug tolerability; female; groups by age; human; International Prostate Symptom Score; long term care; major clinical study; male; micturition disorder; overactive bladder; Overactive Bladder Symptom score; postvoid residual urine volume; priority journal; retrospective study; scoring system; treatment duration; treatment outcome; urine flow rate; uroflowmetry; very elderly; xerostomia; adolescent; chemically induced; constipation; middle aged; overactive bladder; pathophysiology; severity of illness index; time factor; treatment outcome; urodynamics; visual disorder; xerostomia; young adult; Adolescent; Adult; Aged; Aged, 80 and over; Constipation; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Severity of Illness Index; Solifenacin Succinate; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Vision Disorders; Xerostomia; Young Adult
Publisher
Blackwell Publishing
Type
journal article